46234 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 17, 2009, and 

published in the Federal Register on 

April 29, 2009, (74 FR 19599), Norac 

Inc., 405 S. Motor Avenue, P.O. Box 

577, Azusa, California 91702–3232, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Methamphetamine (1105), a basic class 

of controlled substance listed in 

schedule II. 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 USC 823(a) and determined 

that the registration of Norac, Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Norac, Inc. to ensure that 

the company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 USC 823, and 

in accordance with 21 CFR 1301.33, the 

above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: August 21, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21532 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 17, 2009, and 

published in the Federal Register on 

April 29, 2009, (74 FR 19598), Siemens 

Healthcare Diagnostics Inc., Attn: RA, 

100 GBC Drive, Mail Stop 514, Newark, 

Delaware 19702, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company plans to produce the 

listed controlled substances in bulk to 

be used in the manufacture of reagents 

and drug calibrator/controls which are 

DEA exempt products. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siemens Healthcare Diagnostics Inc. to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Siemens Healthcare 

Diagnostics Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21531 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 17, 2009, and 

published in the Federal Register on 

April 29, 2009, (74 FR 19597), Penick 

Corporation, 33 Industrial Road, 

Pennsville, New Jersey 08070, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Drug Schedule 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

The company plans to manufacture 

the listed controlled substances as bulk 

controlled substance intermediates for 

distribution to its customers for further 

manufacture or to manufacture 

pharmaceutical dosage forms. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Penick Corporation to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Penick Corporation to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 21, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21529 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 17, 2009, and 

published in the Federal Register on 

April 29, 2009, (74 FR 19598), AMRI 

Rensselaer, Inc., 33 Riverside Avenue, 

Rensselaer, New York 12144, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 46235 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Dextropropoxyphene, bulk (nondosage form) (9273).II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

AMRI Rensselaer, Inc. to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated AMRI Renssealaer Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 21, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21527 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

United States Parole Commission 

Record of Vote of Meeting Closure 

(Pub. L. 94–409) (5 U.S.C. 552b) 

I, Isaac Fulwood, of the United States 

Parole Commission, was present at a 

meeting of said Commission, which 

started at approximately 2 p.m., on 

Thursday, August 20, 2009, at the U.S. 

Parole Commission, 5550 Friendship 

Boulevard, 4th Floor, Chevy Chase, 

Maryland 20815. The purpose of the 

meeting was to decide one petition for 

reconsideration pursuant to 28 CFR 

Section 2.27. Four Commissioners were 

present, constituting a quorum when the 

vote to close the meeting was submitted. 

Public announcement further 

describing the subject matter of the 

meeting and certifications of General 

Counsel that this meeting may be closed 

by vote of the Commissioners present 

were submitted to the Commissioners 

prior to the conduct of any other 

business. Upon motion duly made, 

seconded, and carried, the following 

Commissioners voted that the meeting 

be closed: Isaac Fulwood, Cranston J. 

Mitchell, Edward F. Reilly, Jr. and 

Patricia K. Cushwa. 

In witness whereof, I make this official 

record of the vote taken to close this 

meeting and authorize this record to be 

made available to the public. 

Dated: August 27, 2009. 

Isaac Fulwood, 

Chairman, U.S. Parole Commission. 

[FR Doc. E9–21498 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–01–M 

DEPARTMENT OF LABOR 

Office of the Secretary 

Submission for OMB Review: 

Comment Request 

September 1, 2009. 

The Department of Labor (DOL) 

hereby announces the submission of the 

following public information collection 

requests (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995 

(Pub. L. 104–13, 44 U.S.C. chapter 35). 

A copy of each ICR, with applicable 

supporting documentation; including 

among other things a description of the 

likely respondents, proposed frequency 

of response, and estimated total burden 

may be obtained from the RegInfo.gov 

Web site at http://www.reginfo.gov/ 

public/do/PRAMain or by contacting 

Mary Beth Smith-Toomey on 202–693– 

4223 (this is not a toll-free number)/ 

e-mail: DOL_PRA_PUBLIC@dol.gov. 

Interested parties are encouraged to 

send comments to the Office of 

Information and Regulatory Affairs, 

Attn: OMB Desk Officer for the 

Department of Labor—VETS, Office of 

Management and Budget, Room 10235, 

Washington, DC 20503, Telephone: 

202–395–7316/Fax: 202–395–5806 

(these are not toll-free numbers), E-mail: 

OIRA_submission@omb.eop.gov within 

30 days from the date of this publication 

in the Federal Register. In order to 

ensure the appropriate consideration, 

comments should reference the OMB 

Control Number (see below). 

The OMB is particularly interested in 

comments which: 

• Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

• Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

• Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

• Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Agency: Office of the Assistance 

Secretary for Administration and 

Management. 

Type of Review: Extension without 

change of an existing OMB Control 

Number. 

Title of Collection: Customer 

Satisfaction Surveys and Conference 

Evaluations Generic Clearance. 

OMB Control Number: 1225–0059. 

Affected Public: Individuals. 

Total Estimated Number of 

Respondents: 200,000. 

Total Estimated Annual Burden 

Hours: 20,000. 

Total Estimated Annual Costs Burden 

(does not include hourly wage costs): $0. 

Description: The Department is 

requesting OMB approval for the 

continued use of a generic clearance 

process for customer satisfaction and 

conference evaluation surveys. 

Customer satisfaction and conference 

evaluation surveys provide important 

information on customer attitudes about 

the delivery and quality of agency 

products and services and will be used 

as part of an ongoing process to improve 

DOL products and products. For 

additional information, see related 

notice published at Volume 74 FR 

26426 on June 2, 2009. 

Agency: Office of the Assistance 

Secretary for Administration and 

Management. 

Type of Review: Extension without 

change of an existing OMB Control 

Number. 


jlentini on DSKJ8SOYB1PROD with NOTICES